Prevention and Treatment of Prostate Cancer: Technologies and Global Markets

  • ID: 4188651
  • Report
  • Region: Global
  • 356 Pages
  • BCC Research
1 of 6
The Global Market for Prostate Cancer Products Reached Nearly $47.2 Billion in 2016 and Should Reach Nearly $65.1 Billion in 2021, with a CAGR of 6.6%

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca
  • CZ BioMed Corp.
  • GE Healthcare
  • Johnson & Johnson
  • Oncogenex
  • MORE

Report Includes

  • An overview of the market for the prevention and treatment of prostate cancer, with coverage of the mechanisms of disease development, detection and diagnosis, and anticancer agents
  • Analyses of global market trends, with data from 2012, 2016, and projections of compound annual growth rates (CAGRs) through 2021
  • Discussion of risk factors, natural history, epidemiology, and the genetics of prostate cancer
  • Examinations of prostate-specific antigen (PSA) screening, including the causes of PSA changes, PSA thresholds, and controversies over the screening
  • Coverage of emerging therapies, including combination therapy, therapeutic vaccines, inhibitors of kinase signaling pathways, proteasome inhibitors, angiogenesis inhibitors, and immunotherapeutic agents
  • Evaluation of prostate cancer treatment products by geography, race, and category
  • Breakdown of the industry structure, including market shares, trends in price and price performance, and factors influencing demand
  • Comprehensive company profiles of major players in the field.

Report Scope

The scope of this study is testing, screening technology and also therapeutics markets for prostate cancer. The report also includes the regulatory environment, current technologies, new technologies, prostate cancer incidence, market projections and market share, along with latest trends and new developments.

Screening for diagnosis, therapy via drug, surgery or radiation is measured and broken down by PSA testing, digital rectal exam (DRE), prostate biopsy, hormone therapy, chemotherapy, immunotherapy, external beam radiation therapy (EBRT), prostatectomy and brachytherapy.

Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca
  • CZ BioMed Corp.
  • GE Healthcare
  • Johnson & Johnson
  • Oncogenex
  • MORE

1: Introduction

  • Study goals and objectives
  • Reasons for doing this study
  • Intended audience
  • Scope of report
  • Information sources

2: Summary and Highlights

  • Table 1 : Summary Table: Global prostate cancer market, through 2021
  • Figure 1 : Summary Figure: Global prostate cancer market, 2012-2021

3: Overview

  • Introduction
  • U.S. Preventive Services Task Force recommendations
  • Biology of prostate cancer
  • Prostate gland function
  • Types of prostate cancer

4: Prostate Cancer Information

  • Detection and diagnosis
  • Conclusion

5: Prostate Cancer Screening and Diagnosis

  • Prostate cancer screening, diagnosis and prognosis
  • Conclusion
  • Table 18 : Prostate cancer diagnosis and treatment strategy

6: Prostate Cancer: Therapeutic Interventions

  • Treatment plan
  • Conclusion

7: Prostate Cancer Therapeutics in the Global Market

  • What is cancer?

8: Global Burden of Cancer

  • Global prostate cancer statistics
  • Conclusion
  • Table 44 : Global cancer incidence estimates, 2013
  • Figure 14 : Global cancer incidence estimates, 2013
  • Table 45 : Cancer in 2013
  • Table 46 : World cancer statistics for the most common cancers, 2012

9: Prostate Cancer and Diagnostic Market

  • Screening tests
  • Prostate cancer market size
  • Prostate cancer diagnostic imaging market

10: Prostate Cancer Treatment Market

  • Treatment plan for prostate cancer

11: Prostate Cancer Drugs Market

  • Global oncology therapeutics market
  • Generic prostate cancer drugs
  • Newer therapies on the market
  • Prostate cancer: therapeutic drugs landscape
  • Conclusion

12: Emerging Prostate Cancer Drugs

  • Emerging products
  • Not approved drugs
  • Conclusion

13: Prostate Cancer Patents

  • Prostate cancer drug patents expiry
  • Conclusion
  • Table 143 : Prostate cancer patent trends, 2002-2011
  • Table 144 : Patents by treatment category, 2002-2011

14: Selected Company Profiles

  • Abbott Laboratories
  • Active Biotech AB
  • Algeta
  • Amgen
  • Astellas Pharma US
  • AstraZeneca
  • Atrix Laboratories
  • Bavarian Nordic A/S
  • Bayer HealthCare Pharmaceuticals
  • Bristol-Myers Squibb
  • C.R. Bard
  • CZ BioMed Corp.
  • Dendreon Corp.
  • DiagnoCure
  • Exelixis
  • Exosome Diagnostics
  • GE Healthcare
  • Genomic Health
  • GlaxoSmithKline
  • Hologic
  • Intuitive Surgical
  • Johnson & Johnson
  • Medivation
  • Metamark
  • Millennium Pharmaceuticals
  • Myriad Genetics
  • Northwest Biotherapeutics
  • Oncogenex
  • Opko Health
  • Pfizer
  • Sanofi
  • Siemens AG
  • Spectrum Pharmaceuticals
  • Varian Medical Systems

15: References and End Notes

  • References
  • End notes

List of Tables

Table 1 : Summary Table: Global prostate cancer market, through 2021
Table 2 : U.S. Preventive Services Task Force Recommendations, 2008
Table 3 : Growth factors implicated in prostate cancer
Table 4 : Proposed prostate cancer susceptibility loci
Table 5 : Important genes in the development of prostate cancer
Table 6 : Mutated genes and abnormal protein expression
Table 7 : Why PSA testing?
Table 8 : Signs and symptoms
Table 9 : Guideline statements
Table 10 : Prostate cancer: major points
Table 11 : ACS recommendations for the early detection of cancer in average-risk, asymptomatic individuals
Table 12 : Prostate cancer screening
Table 13 : Limitations of PSA testing
Table 14 : PSA test: why and when?
Table 15 : Age-specific reference ranges for serum PSA
Table 16 : Other causes of changes in PSA level
Table 17 : Improvements to the PSA test
Table 18 : Prostate cancer diagnosis and treatment strategy
Table 19 : Prostate cancer tests
Table 20 : Prostate cancer: local and metastatic symptoms
Table 21 : Diagnostic methods
Table 22 : Treatment options for prostate cancer
Table 23 : Factors for prostate cancer treatment planning
Table 24 : Guide to prostate cancer diagnosis and management
Table 25 : Stage I prostate cancer
Table 26 : Stage II prostate cancer
Table 27 : Stage III prostate cancer
Table 28 : Stage IV prostate cancer
Table 29 : Types of surgeries
Table 30 : Advantages and disadvantages of radical prostatectomy
Table 31 : Advantages and disadvantages of interstitial brachytherapy
Table 32 : Advantages and disadvantages of external beam radiotherapy
Table 33 : Advantages and disadvantages of cryotherapy
Table 34 : Advantages and disadvantages of ultrasound
Table 35 : Hormone therapy
Table 36 : Common cancers: global cancer cases, 2012
Table 37 : Therapeutics for prostate cancer treatment
Table 38 : Approved FDA prostate cancer drugs
Table 39 : Common drugs for treatment of prostate cancer
Table 40 : Xtandi
Table 41 : Xofigo/Alpharadin
Table 42 : Cabozantinib
Table 43 : Therapeutic agents for prostate cancer under clinical development
Table 44 : Global cancer incidence estimates, 2013
Table 45 : Cancer in 2013
Table 46 : World cancer statistics for the most common cancers, 2012
Table 47 : Incidence and deaths for prostate cancer, 2013
Table 48 : Prostate cancer incidence and mortality global, 2012
Table 49 : Highest incidence of prostate cancer, by country, 2012
Table 50 : Global estimated prostate cancer deaths: age-standardized mortality rates per 100,000 men, 2012
Table 51 : Global estimated new cases of prostate cancer, 2008-2030
Table 52 : Prostate cancer statistics, 2016
Table 53 : Prostate cancer cases and deaths in the U.S., 2008-2016
Table 54 : Prostate cancer statistics: new cases and deaths in the U.S., by race, 2007-2012
Table 55 : Prostate cancer stage and survival rate
Table 56 : Estimated prostate cancer new cases in the U.S., 2012-2030
Table 57 : Incidence rates by race in the U.S., 2005-2009
Table 58 : Estimated prostate cancer new cases in the U.S., 2020-2030
Table 59 : Mortality rates by race in the U.S., 2005-2009
Table 60 : Distribution and five-year relative survival by stage at diagnosis for males of all races, 2002-2008
Table 61 : Relative survival rate for prostate cancer patients
Table 62 : Five-year relative survival by stage at the time of diagnosis
Table 63 : Estimated prostate cancer in Canada, 2015
Table 64 : Estimated prostate cancer mortality in EU27 countries: age-standardized mortality rates per 100,000 men, 2012
Table 65 : Prostate cancer deaths in the U.K.: rate per 100,000 people, 2014
Table 66 : Estimated prostate cancer diagnosed in 2016
Table 67 : Types of diagnostic tests
Table 68 : Global PSA test sales and forecast, through 2021
Table 69 : U.S. PSA test sales and forecast, through 2021
Table 70 : European PSA test sales and forecast, through 2021
Table 71 : Emerging markets PSA test sales and forecast, through 2021
Table 72 : Canadian PSA test sales and forecast, through 2021
Table 73 : Global digital rectal examination sales and forecast, through 2021
Table 74 : U.S. digital rectal examination sales and forecast, through 2021
Table 75 : ROW digital rectal examination sales and forecast (excluding the U.S.), through 2021
Table 76 : Global estimated cost and forecast of prostate biopsies, through 2021
Table 77 : U.S. estimated cost and forecast of prostate biopsies, through 2021
Table 78 : ROW estimated cost and forecast of prostate biopsies (excluding the U.S.), through 2021
Table 79 : Global estimated cost and forecast for prostate biopsies, by region, through 2021
Table 80 : Global prostate cancer screening sales and forecast, through 2021
Table 81 : Manufacturers/suppliers of prostate cancer diagnostics market, 2016
Table 82 : Newer tests and characteristics
Table 83 : List of available prostate nomograms
Table 84 : Global market for prostate cancer imaging technologies: sales and forecast, through 2021
Table 85 : Prostate cancer therapeutic options when local therapy fails
Table 86 : Cost of the three leading prostate cancer therapies, 2012
Table 87 : Key players of surgical device and radiotherapy companies
Table 88 : Global prostate cancer surgery and radiotherapy market sales and forecast, through 2021
Table 89 : Global market for external beam radiation therapy sales and forecast, through 2021
Table 90 : Global brachytherapy market sales and forecast, through 2021
Table 91 : Global estimated incidence of prostate cancer, 2008-2030
Table 92 : Global estimated cases of prostate surgeries performed per year, 2011-2021
Table 93 : Global market for prostate surgeries sales and forecast, through 2021
Table 94 : Global cases of estimated robotic prostatectomies performed per year, 2011-2021
Table 95 : Global market for robotic prostatectomy sales and forecast, through 2021
Table 96 : Global market for estimated open prostatectomy surgeries per year, 2011-2021
Table 97 : Global market for open prostatectomy sales and forecast, through 2021
Table 98 : U.S. urological device market sales and forecast, through 2016
Table 99 : U.S. brachytherapy market sales and forecast, through 2021
Table 100 : Prostate cancer incidence in the U.S., 2008-2016
Table 101 : U.S. total estimated prostatectomy cases, 2011-2021
Table 102 : U.S. robotic prostatectomy market sales and forecast, through 2021
Table 103 : U.S. prostatectomy surgeries sales and forecast, through 2021
Table 104 : U.S. open prostatectomy market sales and forecast, through 2021
Table 105 : Global cancer therapeutic market, through 2021
Table 106 : Oncology pipeline, 2016
Table 107 : Global cytotherapeutics market, 2010 and 2016
Table 108 : Cytotoxic therapies market indications
Table 109 : Expiry of patents on major cytotoxic drugs
Table 110 : U.S. cytotherapeutics market, through 2016
Table 111 : European cytotherapeutics market, through 2016
Table 112 : Japanese cytotherapeutics market, through 2016
Table 113 : Major cytotoxic brands sales, 2016
Table 114 : Drug products and treatment market for prostate cancer, through 2021
Table 115 : Current prostate cancer therapies and costs
Table 116 : Prostate cancer drug market, through 2021
Table 117 : Prostate cancer drug products, by treatment category, through 2021
Table 118 : U.S. prostate cancer market: patients and treatment strategies
Table 119 : New drugs and sales forecast, 2015 and 2021
Table 120 : Global sales and forecast: key prostate cancer drugs, 2010-2016
Table 121 : Global prostate cancer chemotherapy drugs
Table 122 : Global chemotherapy market for prostate cancer sales and forecast, through 2021
Table 123 : Key chemotherapeutic drugs for prostate cancer sales and forecast, 2010-2016
Table 124 : Global prostate cancer hormonal therapy drugs
Table 125 : Hormone therapy for prostate cancer sales and forecast, through 2021
Table 126 : Generics sales and forecast, through 2021
Table 127 : Casodex sales and forecast, through 2021
Table 128 : Zytiga sales estimates, 2012 and 2015
Table 129 : Global sales and forecast for Zytiga, through 2021
Table 130 : Global market sales and forecast for Xtandi, through 2021
Table 131 : Global market for Flutamide, 2009-2010
Table 132 : Global market for Triptorelin, 2009-2010
Table 133 : Global market for Lupron, through 2021
Table 134 : Global market for Zoladex sales and forecast, through 2021
Table 135 : Global prostate cancer immunotherapy drug sales and forecast, through 2021
Table 136 : Provenge annual sales and forecast, 2010-2016
Table 137 : Global market for prostate cancer care, by region, through 2021
Table 138 : European prostate cancer care market, through 2021
Table 139 : U.S. prostate cancer care market, through 2021
Table 140 : Canadian prostate cancer care market, through 2021
Table 141 : Global prostate cancer market sales and forecast, through 2021
Table 142 : Emerging products for prostate cancer
Table 143 : Prostate cancer patent trends, 2002-2011
Table 144 : Patents by treatment category, 2002-2011
Table 145 : Expiry of patents on major brands
Table 146 : List of key Dendreon patents and patent applications

List of Figures

Figure 1 : Summary Figure: Global prostate cancer market, 2012-2021
Figure 2 : Chemical structure of Casodex
Figure 3 : Chemical structure of Zoladex
Figure 4 : Chemical structure of Eligard
Figure 5 : Chemical structure of Nilandron
Figure 6 : Chemical structure of Flutamide
Figure 7 : Chemical structure of Trelstar
Figure 8 : Chemical structure of Estramustine
Figure 9 : Chemical structure of Firmagon
Figure 10 : Chemical structure of Docetaxel
Figure 11 : Chemical structure of Jevtana
Figure 12 : Chemical structure of Zytiga
Figure 13 : Chemical structure of Xtandi
Figure 14 : Global cancer incidence estimates, 2013
Figure 15 : Prostate cancer incidence and mortality global, 2012
Figure 16 : Global estimated prostate cancer deaths: age-standardized mortality rates per 100,000 men, 2012
Figure 17 : Global estimated new cases of prostate cancer, 2008-2030
Figure 18 : Prostate cancer cases and deaths in the U.S., 2008-2016
Figure 19 : Estimated prostate cancer new cases in the U.S., 2012-2030
Figure 20 : Estimated prostate cancer new cases in the U.S., 2020-2030
Figure 21 : Estimated prostate cancer mortality in EU27 countries: age-standardized mortality rates per 100,000 men, 2012
Figure 22 : Prostate cancer deaths in the U.K.: rate per 100,000 people, 2014
Figure 23 : Global PSA test sales and forecast, 2010-2021
Figure 24 : U.S. PSA test sales and forecast, 2011-2021
Figure 25 : European PSA test sales and forecast, 2011-2021
Figure 26 : Canadian PSA test sales and forecast, 2011-2021
Figure 27 : Global digital rectal examination sales and forecast, 2012-2021
Figure 28 : U.S. digital rectal examination sales and forecast, 2016 and 2021
Figure 29 : ROW digital rectal examination sales and forecast (excluding the U.S.), 2012-2021
Figure 30 : Global estimated cost and forecast of prostate biopsies, 2012-2021
Figure 31 : U.S. estimated cost and forecast of prostate biopsies, 2012-2021
Figure 32 : Emerging markets PSA test sales and forecast, 2010-2021
Figure 33 : ROW estimated cost and forecast of prostate biopsies (excluding the U.S.), 2012-2021
Figure 34 : Global estimated cost and forecast for prostate biopsies, by region, 2012-2021
Figure 35 : Global prostate cancer screening sales and forecast, 2012-2021
Figure 36 : Global market for prostate cancer imaging technologies: sales and forecast, 2012-2021
Figure 37 : Global prostate cancer surgery and radiotherapy market sales and forecast, 2012-2021
Figure 38 : Global market for external beam radiation therapy sales and forecast, 2012-2021
Figure 39 : Global brachytherapy market sales and forecast, 2012-2021
Figure 40 : Global estimated incidence of prostate cancer, 2008-2030
Figure 41 : Global estimated cases of prostate surgeries performed per year, 2011-2021
Figure 42 : Global market for prostate surgeries sales and forecast, 2012-2021
Figure 43 : Global cases of estimated robotic prostatectomies performed per year, 2011-2021
Figure 44 : Global market for robotic prostatectomy sales and forecast, 2012-2021
Figure 45 : Global market for estimated open prostatectomy surgeries per year, 2011-2021
Figure 46 : Global market for open prostatectomy sales and forecast, 2012-2021
Figure 47 : U.S. brachytherapy market sales and forecast, 2012-2021
Figure 48 : Prostate cancer incidence in the U.S., 2008-2016
Figure 49 : U.S. robotic prostatectomy market sales and forecast, 2011-2021
Figure 50 : U.S. prostatectomy surgeries sales and forecast, 2012-2021
Figure 51 : U.S. open prostatectomy market sales and forecast, 2012-2021
Figure 52 : Global cancer therapeutic market, 2016 and 2021
Figure 53 : U.S. cytotherapeutics market, 2010-2016
Figure 54 : European cytotherapeutics market, 2010-2016
Figure 55 : Japanese cytotherapeutics market, 2010-2016
Figure 56 : Drug products and treatment market for prostate cancer, 2012-2021
Figure 57 : Prostate cancer drug market, 2012-2021
Figure 58 : Prostate cancer drug products, by treatment category, 2012-2021
Figure 59 : Global chemotherapy market for prostate cancer sales and forecast, 2010-2021
Figure 60 : Hormone therapy for prostate cancer sales and forecast, through 2021
Figure 61 : Casodex sales and forecast, 2011-2021
Figure 62 : Zytiga sales estimates, 2012 and 2015
Figure 63 : Global sales and forecast for Zytiga, 2011-2021
Figure 64 : Global market for Zoladex sales and forecast, 2009-2021
Figure 65 : Global prostate cancer immunotherapy drug sales and forecast, 2010-2021
Figure 66 : Provenge annual sales and forecast, 2010-2016
Figure 67 : Global market for prostate cancer care, by region, 2012-2021
Figure 68 : European prostate cancer care market, 2012-2021
Figure 69 : U.S. prostate cancer care market, 2012-2021
Figure 70 : Canadian prostate cancer care market, 2012-2021
Figure 71 : Global prostate cancer market sales and forecast, through 2021

Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca
  • CZ BioMed Corp.
  • GE Healthcare
  • Johnson & Johnson
  • Oncogenex
  • MORE

Analyst Credentials:

Usha Nagavarapu is an experienced pharmaceutical professional with scientific and business development experience. She has managed preclinical discovery programs from target identification, including investigational new drug (IND) enabling studies, and assisted out-licensing and portfolio development activities. Her strong focus areas include oncology, dermatology and cardiovascular diseases. She has extensive experience working with early start-ups to fulfill operational obligations while minimizing overall operational cost and burden.

Note: Product cover images may vary from those shown
5 of 6
  • Abbott Laboratories
  • Active Biotech AB
  • Algeta
  • Amgen
  • Astellas Pharma US
  • AstraZeneca
  • Atrix Laboratories
  • Bavarian Nordic A/S
  • Bayer HealthCare Pharmaceuticals
  • Bristol-Myers Squibb
  • C.R. Bard
  • CZ BioMed Corp.
  • Dendreon Corp.
  • DiagnoCure
  • Exelixis
  • Exosome Diagnostics
  • GE Healthcare
  • Genomic Health
  • GlaxoSmithKline
  • Hologic
  • Intuitive Surgical
  • Johnson & Johnson
  • Medivation
  • Metamark
  • Millennium Pharmaceuticals
  • Myriad Genetics
  • Northwest Biotherapeutics
  • Oncogenex
  • Opko Health
  • Pfizer
  • Sanofi
  • Siemens AG
  • Spectrum Pharmaceuticals
  • Varian Medical Systems
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll